Jove
Visualize
Contact Us

Related Experiment Videos

Dry powder inhalers: an overview.

Paul J Atkins1

  • 1Oriel Therapeutics, Research Triangle Park, North Carolina 27709, USA. patkins@orieltherapeutics.com

Respiratory Care
|September 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Richard William Fuller-The Clinical Scientist Behind the Development of Multiple Leading Inhaled Therapies for Asthma (b. June 29, 1953-d. 2024).

Journal of aerosol medicine and pulmonary drug delivery·2025
Same author

Richard William Fuller-The Clinical Scientist Behind the Development of Multiple Leading Inhaled Therapies for Asthma (b. June 29, 1953-d. 2024).

Journal of aerosol medicine and pulmonary drug delivery·2025
Same author

A brief description of the biomechanics and physiology of a strongman event: the tire flip.

Journal of strength and conditioning research·2010
Same journal

Response to the Letter to the Editor Regarding "Comparative Evaluation of Risk Scores for Predicting Postoperative Pulmonary Complications".

Respiratory care·2026
Same journal

Respiratory Muscle Dysfunction in Stable COPD: A Multimodal Assessment of Diaphragmatic and Cough-Related Impairment.

Respiratory care·2026
Same journal

Flow Asynchronies During Pressure Support Ventilation in Children: A Bench Model Study.

Respiratory care·2026
Same journal

Inspiratory Effort Assessment Using the Occlusion Pressure-Derived Tension-Time Index.

Respiratory care·2026
Same journal

Clinical Usage of High-Flow Nasal Cannula Across Disease Categories and Care Settings: A Nationwide Cohort Study in Japan.

Respiratory care·2026
Same journal

Efficacy of Mechanical Insufflation-Exsufflation Devices as Analyzed in Lung Models: Systematic Review and Network Meta-Analysis of Peak Expiratory Flow Data.

Respiratory care·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Dry powder inhalers (DPIs) are crucial for delivering asthma and COPD medications, with advancements improving patient convenience and compliance. Optimizing formulation and device design is key for effective pulmonary drug delivery.

Area of Science:

  • Pharmaceutical Technology
  • Respiratory Medicine
  • Drug Delivery Systems

Background:

  • Dry powder inhalers (DPIs) are a preferred inhaled dosage form in Europe for asthma and COPD treatment.
  • DPI adoption in the US has grown significantly, driven by successful combination therapies like Advair Diskus.
  • DPIs offer enhanced patient convenience and compliance, especially for combination therapies.

Purpose of the Study:

  • To highlight the importance of Dry Powder Inhalers (DPIs) in modern respiratory medicine.
  • To discuss the complexities and key factors in designing effective DPIs.
  • To emphasize the critical role of aerosol quality in pulmonary drug delivery.

Main Methods:

  • Review of current trends and challenges in DPI development.

Related Experiment Videos

  • Analysis of formulation-device interactions and particle engineering.
  • Discussion of patient interface and aerosol performance metrics.

    • Main Results:

    • DPIs have become a standard for pulmonary delivery due to convenience and compliance.
    • Successful DPIs require careful optimization of formulation, device geometry, and particle characteristics.
    • Achieving a high-quality aerosol with appropriate aerodynamic particle size is essential for effective lung deposition.

    Conclusions:

    • DPIs are a vital tool in managing respiratory diseases, with ongoing innovation focusing on device-integrated energy and improved patient interaction.
    • The success of DPIs hinges on the synergistic relationship between drug formulation and device engineering.
    • Consistent and effective lung deposition, driven by optimal aerosol properties, remains the ultimate goal for DPI performance.